A physical examination performed after her referral was normal, with nothing out of the ordinary being seen with regard to the complete blood count (CBC), biochemical parameters, or cardiac troponin I levels. The ECG showed negative T-waves in the V1-V6 leads and slight ST depression in the V4-V6 leads (Figure 1) while the echocardiography detected myocardial hypertrophy that was mostly confined to the apical portion of the LV, resulting in a spadelike configuration of the LV cavity at end-diastole (Figure 2). In addition, the systolic function of the LV was normal (fractional shortening 41%), and the LV dimension at the basal level had increased to 43 mm. Color echocardiography revealed mild mitral regurgitation but no intracavitary LV obstruction. The end-diastolic thickness of the LV apical-free wall and the basal-free wall were 15 mm and 8.3 mm, respectively while the end-diastolic thickness of the apical interventricular septum (IVS) and basal IVS were 16 mm and 7.2 mm, respectively. Furthermore, the maximal apical to posterior wall thickness ratio was 1.8. The patient was also evaluated via a 24-hour Holter monitor, and this yielded normal results.
Figure 1: The patient’s ECG showing the negative T-waves in the V1-V6 leads.
Figure 2: Transthoracic echocardiography showing the parasternal short-axis view.
The diagnosis of AHCM is normally made via either two-dimensional echocardiography or magnetic resonance imaging (MRI) and is based on the presence of an otherwise unexplained asymmetric hypertrophy of the LV that is confined predominantly to the LV apex with a maximal apical wall thickness of ≥15 mm and a maximal apical to posterior wall thickness of ≥1.5.[5] In borderline cases with a maximal wall thickness of between 13 and 15 mm, concomitant ECG changes are required to establish the diagnosis of AHCM.[6]
Apical hypertrophic cardiomyopathy can further be subdivided into two groups: the “pure apical” form with isolated apical hypertrophy which is limited to the LV apex below the papillary muscle level and the “distal dominant” form in which the apical hypertrophy extends to other segments, including the IVS and the LV anterior and posterior walls.[7] Our patient had the “pure apical” form of AHCM.
In contrast to the other variants of HCM, the prognosis of AHCM is comparatively benign. Eriksson et al.[8] reported an overall mortality rate of 10.5% for these patients while the cardiovascular mortality rate was 1.9% after a follow-up period of 13.6±8.3 years. The “pure-apical” form of AHCM is generally associated with a benign clinical manifestation, whereas the outlook for patients with the “distaldominant” form is not as positive and more closely resembles the clinical manifestation of typical HCM.[7] The study by Miyamoto et al.[2] featured two children with AHCM, and both remained asymptomatic for more than 15 years. Our patient had no complaints during her one-year follow-up period.
Declaration of conflicting interests
The authors declared no conflicts of interest with
respect to the authorship and/or publication of this
article.
Funding
The authors received no financial support for the
research and/or authorship of this article.
1) Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant
T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic
and ultrasono-cardiotomographic study. Jpn Heart J
1976;17:611-29.
2) Miyamoto T, Horigome H, Kawano S, Sumazaki R. Apical
hypertrophic cardiomyopathy in childhood: a long-term
follow-up report of two cases. Pediatr Cardiol 2009;30:343-6.
3) Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron
BJ. Comparison of prevalence of apical hypertrophic
cardiomyopathy in Japan and the United States. Am J Cardiol
2003;92:1183-6.
4) Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid
M, Ho CY, et al. Gene mutations in apical hypertrophic
cardiomyopathy. Circulation 2005;112:2805-11.
5) Maron BJ, McKenna WJ, Danielson GK, Kappenberger
LJ, Kuhn HJ, Seidman CE, et al. American College of
Cardiology/European Society of Cardiology Clinical Expert
Consensus Document on Hypertrophic Cardiomyopathy. A
report of the American College of Cardiology Foundation
Task Force on Clinical Expert Consensus Documents and
the European Society of Cardiology Committee for Practice
Guidelines. Eur Heart J 2003;24:1965-91.
6) McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda
M. Experience from clinical genetics in hypertrophic
cardiomyopathy: proposal for new diagnostic criteria in adult
members of affected families. Heart 1997;77:130-2.